In a 75‑kg adult patient, how should a norepinephrine preparation of 16 mg/15 mL be diluted (including diluent and final concentration) and what infusion rates should be used for titration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Norepinephrine Dilution and Titration for 16mg/15mL Preparation in a 75kg Patient

For a 16mg/15mL norepinephrine preparation, dilute the entire 15mL into 235mL of 5% dextrose (D5W) to create a standard 250mL solution with a final concentration of 64 mcg/mL (16,000 mcg ÷ 250mL), then start the infusion at 7.5-37.5 mcg/min (7-35 mL/hr) and titrate to maintain MAP ≥65 mmHg. 1

Dilution Protocol

Diluent Selection:

  • Use 5% dextrose in water (D5W) or 5% dextrose with sodium chloride as the primary diluent 1
  • Do NOT use normal saline alone - dextrose-containing solutions protect against oxidation and loss of potency 1
  • The solution remains chemically stable for 7 days at room temperature under ambient light in either D5W or NS, though D5W is preferred per FDA labeling 2

Standard Dilution Method:

  • Add your 15mL (containing 16mg = 16,000 mcg) to 235mL of D5W
  • Final volume: 250mL
  • Final concentration: 64 mcg/mL (16,000 mcg ÷ 250mL)

This creates a more concentrated solution than the standard FDA-recommended 4 mcg/mL, but remains within acceptable ranges for central line administration 1.

Administration Route

Central venous access is strongly preferred - norepinephrine and other catecholamines cause severe tissue necrosis if extravasation occurs 3. If extravasation develops, immediately infiltrate 5-10mg of phentolamine diluted in 10-15mL saline into the affected site 3, 4.

Titration Protocol for 75kg Patient

Starting Dose:

  • Begin at 0.1 mcg/kg/min = 7.5 mcg/min for this 75kg patient 3
  • With your 64 mcg/mL concentration: 7 mL/hr delivers approximately 7.5 mcg/min
  • Observe response for 2-3 minutes before adjusting 1

Dose Range:

  • Initial titration range: 0.1-0.5 mcg/kg/min (7.5-37.5 mcg/min in 75kg patient) 3
  • With your concentration, this translates to 7-35 mL/hr
  • Adjust rate to establish and maintain MAP ≥65 mmHg 5

Titration Strategy:

  • Increase by 2-4 mcg/min increments (approximately 2-4 mL/hr with your concentration) every 2-3 minutes based on blood pressure response 1
  • Target MAP of 65 mmHg is the evidence-based goal for most patients 5
  • In previously hypertensive patients, avoid raising BP more than 40 mmHg below their baseline systolic pressure 1

High-Dose Considerations:

  • Doses may occasionally need to exceed 0.5 mcg/kg/min if hypotension persists 3
  • Always suspect occult hypovolemia if requiring escalating doses - ensure adequate volume resuscitation first 1
  • Central venous pressure monitoring is helpful for detecting volume depletion 1

Critical Monitoring Parameters

Continuous monitoring required:

  • Blood pressure (arterial line preferred for continuous monitoring)
  • Heart rate and cardiac rhythm
  • Urine output (should achieve >100 mL/hr initially) 6
  • Signs of peripheral perfusion (skin temperature, color, capillary refill)
  • IV site for extravasation 3

Important Caveats

Volume Status First: Blood volume depletion must be corrected as fully as possible before starting norepinephrine, though it can be given concurrently with volume resuscitation in emergency situations 1.

Weight-Based Dosing Consideration: Recent evidence shows obese patients require lower weight-based doses but similar absolute doses compared to non-obese patients 7. For a 75kg patient of normal BMI, standard weight-based dosing applies.

Compatibility: Do not mix norepinephrine with sodium bicarbonate or other alkaline solutions - adrenergic agents are inactivated in alkaline environments 3. Avoid contact with iron salts, alkalis, or oxidizing agents 1.

Solution Inspection: Discard if solution is pinkish, darker than slightly yellow, or contains precipitate 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.